Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 1 de 1
Filtrar
Añadir filtros








Intervalo de año
1.
Iranian Journal of Dermatology. 2009; 11 (4): 159-167
en Inglés | IMEMR | ID: emr-109739

RESUMEN

Psoriasis is a chronic, genetically determined skin disease. A variety of biochemical and molecular biological alterations have been identified, but the pathogenesis of psoriasis is still not clear. For patients with mild to moderate psoriasis, topical therapies are generally used. However, approximately one-third of the patients have a moderate to severe psoriasis and need a systemic therapy. Beside well known therapeutical approaches, e.g. PUVA, retinoids, ciclosporine A, methotrexate or fumaric acid derivatives, innovative therapeutical strategies have been developed recently. Fusion proteins [e.g. alefacept, denileukin diftitox, etanercept], monoclonal antibodies [e.g. adalimumab, efalizumab, infliximab] or enzyme inhibitors [e.g. mycophenolate mofetil] have been successfully used in the treatment of patients with severe psoriasis and/or psoriatic arthritis


Asunto(s)
Humanos , Psoriasis/tratamiento farmacológico , Artritis Psoriásica/terapia , Artritis Psoriásica/tratamiento farmacológico , Administración Tópica , Fototerapia
SELECCIÓN DE REFERENCIAS
DETALLE DE LA BÚSQUEDA